Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462014 · ClinicalTrials.gov registry record
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 507
- Enrollment target
NCT06462014 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 507 participants.
The verdict
NCT06462014 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 507 participants
- Enrollment target
Study Summary
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Interventions
- DRUG Relugolix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2024-12-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06462014
The ClinicalTrials.gov registry entry for NCT06462014 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Relugolix is the first listed.
NCT06462014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06462014 about?
NCT06462014 is a clinical study titled "Description of Relugolix Use in Patients With Prostate Cancer Within the VHA". The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
What is the current status of trial NCT06462014?
This trial is currently completed. The enrollment target is 507 participants. The study started on 2024-06-19. Estimated completion is 2024-12-13.
What interventions are being tested in trial NCT06462014?
The interventions under investigation include: Relugolix (DRUG).
Who is sponsoring clinical trial NCT06462014?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.